- Home
- NVCT vs PSF Comparison
NVCT vs PSF Comparison
Compare NVCT & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | PSF |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.4M | 229.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVCT | PSF |
|---|---|---|
| Price | $11.11 | $19.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 79.0K | 42.9K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.69% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $18.95 |
| 52 Week High | $13.34 | $21.20 |
Technical Indicators
Market Signals| Indicator | NVCT | PSF |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 34.05 |
| Support Level | $7.79 | $18.95 |
| Resistance Level | N/A | $20.61 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 54.78 | 9.15 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.